Advertisement

Expert Point of View: Quynh-Thu Le, MD, FACR, FASTRO


Advertisement
Get Permission

In an interview with The ASCO Post, Quynh-Thu Le, MD, FACR, FASTRO, Professor and Chair of Radiation Oncology at Stanford Cancer Center, called this phase II de-escalation trial an “intriguing study” that heads in the right direction for treatment de-escalation. However, Dr. Le noted, the presentation provided only acute toxicity data.

Quynh-Thu Le, MD, FACR, FASTRO

Quynh-Thu Le, MD, FACR, FASTRO

“Crucial clinical information, including treatment outcomes, late effects, and patient-reported outcomes, is not yet available to assess the clinical implications of this approach,” said Dr. Le. “In addition, to be able to generalize such an approach, a large multi-institutional trial comparing this approach of de-escalated treatment with the standard of care is needed.” 

DISCLOSURE: Dr. Le reported no conflicts of interest.


Related Articles

Midtreatment Imaging De-escalates Therapy for Half of Study Patients With Oropharyngeal Cancer

Positron-emission tomography (PET) scans obtained before and midway through treatment may be used to de-escalate therapy for patients with oropharyngeal cancer, leading to fewer side effects, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 An interim...

Advertisement

Advertisement



Advertisement